Key Highlights
- Shares are trading up 13.44% at $164.89 versus a prior close of $145.35.
- Third-quarter net product sales topped $1.1 billion, up more than 40%.
- Full-year Ingrezza guidance was raised again to $2.9 billion to $2.925 billion.
Neurocrine Biosciences (NASDAQ:NBIX) shares are trading up 13.44% at $164.89 today after a third-quarter report that beat expectations, with Revenue topping $1.1 billion for the first time and non-GAAP EPS of $3.29 against consensus near $2.57. The stock sits within a 52-week range of $122.14 to $186.12 on Volume of more than double the average, well ahead of a roughly flat healthcare sector ETF.
Neurocrine is a San Diego-based neuroscience-focused biopharmaceutical company founded in 1992. Its flagship product, Ingrezza, a VMAT2 inhibitor for tardive dyskinesia and Huntington's disease chorea, is complemented by Crenessity for congenital adrenal hyperplasia, Orilissa and Oriahnn for women's health, and the newly acquired Vykat XR from Soleno.
Record Sales and Profitability Beat the Street
Net product sales rose more than 40% year over year to record levels, and the company reported record profitability. Cash was about $800 million after the Soleno deal, Operating Cash Flow was $400 million, and about $100 million went to share repurchases.
Ingrezza sales were $801 million, up 17%, including a $20 million order-timing benefit expected to reverse in the fourth quarter. Full-year Ingrezza guidance was raised again to $2.9 billion to $2.925 billion, and 2026 prescription growth is expected in the high teens. Selling, general and administrative expense guidance was trimmed.
Crenessity Gains Traction and Vykat XR Adds a New Franchise
Crenessity sales were $211 million, with more than 15% of diagnosed classic CAH patients prescribed, steady new starts and strong persistence. Vykat XR contributed $107 million with sequential growth from net patient adds, though management expects a delayed return to growth after recent external safety-related events. A new study in patients with Prader-Willi syndrome and complex health issues is planned for 2027.
For 2027, management expects double-digit Ingrezza volume growth to more than offset mid to high single-digit net price concessions, and formulary access is expected to be at least as good as in 2026. Formal 2027 guidance arrives in February.
Phase 3 Readouts in 2027 and a December R&D Day
The pipeline is advancing, with 2027 Phase 3 readouts expected for osavampator in major depressive disorder and direclidine in schizophrenia. The company is on track for six Phase 1 and five Phase 2 starts this year, and obesity programs NBI-1968 and NBI-2118 are in Phase 1. An R&D Day is set for December 15.
Analysts followed with target increases, including Piper Sandler at $215, Canaccord at $220, RBC at $190, Morgan Stanley at $185 and Deutsche Bank at $175. RBC pointed to a Vykat recovery and a narrowing gap between valuation and fundamentals ahead of the 2027 Phase 3 readouts.
Business Development Flexibility Backs the Growth Plan
Management says it has financial flexibility for Business development but does not need to do a deal. With record sales, a raised Ingrezza outlook and 2027 readouts ahead, the focus turns to the December 15 R&D Day and February guidance.






Please wait processing your request...